[Labeling of leukocytes using stannous 99mTc-colloid in whole blood samples]. / Marcación de leucocitos utilizando coloide estannoso-99mTc a partir de muestras de sangre entera.

This paper presents the preparation of a radiocolloid that still makes it possible to label leukocytes using its phagocytosis capacity. Given that this function is exclusively of the white blood cells, not being exercised by other blood cells, the use of a stannous fluoride radiocolloid labeled with 99mTc (F2Sn-99mTc) was tested in order to label leukocytes in whole blood samples. Using cellular separation techniques in density gradients and acquisition of images in gamma camera of radioactivity distribution in Percol, it was observed that the white cells labeling achieved was selective and with high efficiency for leukocytes (in all cases, it was superior to 70%), optimal reproducibility, low cost and low cellular toxicity.

Marcación de leucocitos utilizando coloide estannoso-99mTc a partir de muestras de sangre entera / Labeling of leukocytes using stannous 99mtc-colloid in whole blood samples

Se presenta la preparación de un radiocoloide que permite la marcación de leucocitos utilizando su capacidad de fagocitosis. Dado que esta función es exclusiva de los glóbulos blancos, no ejerciéndola otras células sanguíneas, se probó la utilización de un coloide de fluoruro estannoso marcado con 99mTc (F2Sn-99mTc) a fin de marcar dichas células en muestras de sangre entera. Mediante técnicas de separación celular en gradientes de densidad y adquisición de imágenes en cámara gamma de la distribución de radioactividad en tubos con Percol 90 por ciento, se observó que la marcación lograda es selectiva y de alta eficiencia para leucocitos (en todos los casos fue mayor del 70 por ciento), óptima reproducibilidad, bajo costo y baja toxicidad celular (AU)

Thyrotropin receptor antibodies in parotid saliva.

Parotid saliva was collected with a Carlson-Crittenden device, under citric acid stimulation, in 18 patients with autoimmune thyroid disease. Thyrotropin Receptor Antibodies (TRAb) were measured with a radioreceptor assay in parotid saliva and in serum in the same patients, and a statistical analysis of the data was performed. TRAb levels in parotid saliva were higher than in serum in the 3 pathologies studied (Graves' disease, Hashitoxicosis and Hashimoto's thyroiditis). There was good correlation between salivary and serum levels.

Multicompartmental analysis of triiodothyronine kinetics in hypothyroid patients treated orally or intravenously with triiodothyronine.

Kinetic studies were performed with i.v. 125I T3 in four athyreotic women on two occasions each, once while they were taking oral T3 (30 micrograms T3 every 12 h) and again while on i.v. T3 replacement (same dosage schedule). The kinetic data were analyzed by a 7-compartment model, representing the plasma volume, the fast and slow peripheral exchange compartments, the iodide pool (as a delay compartment prior to appearance in the urine), the intestine (as a delay compartment before appearance in the feces), and the urine and feces. Modeling was done by the SAAM methodology. All data sets, and also the mean data treated as though they were data from a single subject, were fitted for the two limit solutions in which all metabolism was assumed to be in one or the other of the exchange compartments. The mean data set was also fitted to a solution in which limits were imposed on the excretion parameters and the partition of metabolism between the 2 peripheral exchange compartments was estimated. We found that steady-state parameters for removal of T3 from the circulation (the MCRs and DRs) were increased during the i.v. T3 replacement period compared with the oral replacement period, especially in the fast exchange compartment. Measured serum stable T3 levels (RIA) were lower in the i.v. than in the oral study, both at 8 and at 12 h after the most recent T3 dose. These values corresponded to similar differences in the circulating T3 levels projected from the model, although the T3 values projected from the model were greater than the measured T3 levels for unknown reasons.(ABSTRACT TRUNCATED AT 250 WORDS)

Bone mass in totally thyroidectomized patients. Role of calcitonin deficiency and exogenous thyroid treatment.

Calcitonin has an uncertain role in the preservation of bone mass. Since surgical thyroidectomy abolishes the calcitonin secretion in response to calcium, the bone mineral density at the radius shaft and lumbar spine was measured in 60 patients (5 men, 16 premenopausal, 34 postmenopausal euparathyroid and 5 postmenopausal hypoparathyroid women) who had undergone near total thyroidectomy for thyroid cancer 8.4 +/- 0.7 years before the study. All patients were maintained on suppressive doses of thyroid hormones. Bone mineral density values of the radius shaft (expressed as Z-score) of 34 postmenopausal euparathyroid women was significantly below the normal average (mean +/- SEM = -0.59 +/- 0.2; p = 0.01). Bone mineral density of the lumbar spine was also below the normal average although the difference only approached statistical significance (-0.36 +/- 0.2; 0.05 less than p less than 0.1). The bone mineral density of neither the radius nor the spine differed from normal levels in the premenopausal women and the postmenopausal hypoparathyroid women. Unexpectedly, the bone mineral density of the spine was significantly increased in the 5 thyroidectomized men. The results indicate that thyroidectomized women have a diminished bone mass after the menopause only if parathyroid function is normal. Since the patients were receiving thyroid hormone at suppressive doses, the present study is not able to separate the relative contributions of calcitonin deficit and exogenous thyroid on bone mass loss.

[TSH receptor antibodies as a recurrence index of Graves disease treated with antithyroid drugs]. / Anticuerpos anti-receptor de TSH como índice de recidiva en la enfermedad de Graves tratada con drogas antitiroideas.

TSH receptor antibodies (TRAb) measured by the TBI residual assay (TBIr) were studied in 3 groups of Graves disease patients, as follows: 54 non treated cases (Group 1), 20 cases under methimazol treatment (Group 2) and 23 patients who were euthyroid after one year of methimazol treatment (Group 3), in order to evaluate the usefulness of TBIr as a recurrence index in Graves disease following antithyroid drug treatment. In group 1, TBIr was positive in 77.7% (45/54) of the cases. In group 2: 45% (9/20) had positive values for TBIr, all of which had a recurrence of disease during the year following the suppression of the treatment. In group 3, 69.5% patients (16/23) were TBIr positive. In 75% (12/16) of them the abnormally high values of TBIr predicted the recurrence, while 71.43% (5/7) of the patients, TBIr negatives, continued the remission 12 months later. By comparing the TBIr values before and after treatment in the group 3 patients, different possibilities were observed: a) TBIr persistently elevated: 52.17% (12/23). The 83.3% (10/12) had a recurrence before 6 months following treatment termination. b) TBIr, initially elevated, but later showing 50% decrease or negative values: 26.09% (6/23). Every patient was euthyroid one year after the treatment ended. c) TBIr persistently negative: 13.04% (3/23). Two of them had recurrence of their disease. d) TBIr negative which changed later to positive: 8.70% (2/23). Both presented a recurrence. In accordance with these results, we believe that abnormally high TBIr values before or after treatment is a useful recurrence index.(ABSTRACT TRUNCATED AT 250 WORDS)

Anticuerpos anti-receptor de TSH como índice de recidiva en la enfermedad de Graves tratada con drogas antitiroideas. / [TSH receptor antibodies as a recurrence index of Graves disease treated with antithyroid drugs]

TSH receptor antibodies (TRAb) measured by the TBI residual assay (TBIr) were studied in 3 groups of Graves disease patients, as follows: 54 non treated cases (Group 1), 20 cases under methimazol treatment (Group 2) and 23 patients who were euthyroid after one year of methimazol treatment (Group 3), in order to evaluate the usefulness of TBIr as a recurrence index in Graves disease following antithyroid drug treatment. In group 1, TBIr was positive in 77.7

(45/54) of the cases. In group 2: 45

(9/20) had positive values for TBIr, all of which had a recurrence of disease during the year following the suppression of the treatment. In group 3, 69.5

patients (16/23) were TBIr positive. In 75

(12/16) of them the abnormally high values of TBIr predicted the recurrence, while 71.43

(5/7) of the patients, TBIr negatives, continued the remission 12 months later. By comparing the TBIr values before and after treatment in the group 3 patients, different possibilities were observed: a) TBIr persistently elevated: 52.17

(12/23). The 83.3

(10/12) had a recurrence before 6 months following treatment termination. b) TBIr, initially elevated, but later showing 50

decrease or negative values: 26.09

(6/23). Every patient was euthyroid one year after the treatment ended. c) TBIr persistently negative: 13.04

(3/23). Two of them had recurrence of their disease. d) TBIr negative which changed later to positive: 8.70

(2/23). Both presented a recurrence. In accordance with these results, we believe that abnormally high TBIr values before or after treatment is a useful recurrence index.(ABSTRACT TRUNCATED AT 250 WORDS)